Physician

Veerpal Singh, MBBS,M.D.

According to 2025 Medicare claims, Veerpal Singh, MBBS, M.D. (NPI: 1295952596) practices hematology/oncology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Mc Henry, IL. This provider's primary affiliated billing organization is ILLINOIS CANCER SPECIALISTS (NPI: 1164483913; TIN: 363980044) and primary practice location at 60123-9405.

Singh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 994 traditional Medicare patients, billed 323,988 HCPCS/CPT codes, and received $5,566,435 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,375 prescription claims across 431 beneficiaries totaling $6,249,287 in drug costs, led by Revlimid (Lenalidomide). DME data shows 28 claims. Open Payments data shows 137 records totaling $3,788. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $3,108,115 to $5,566,435. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $797,829 to $6,249,287. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,195 to $620.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,041	320,609	$3,108,115
2016	1,010	249,459	$3,289,353
2017	1,025	285,549	$5,335,833
2018	1,130	277,124	$4,681,859
2019	1,124	282,202	$5,076,791
2020	1,093	405,044	$5,470,006
2021	1,033	363,216	$6,074,667
2022	983	343,485	$5,304,956
2023	998	402,509	$5,996,664
2024	994	323,988	$5,566,435

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	262	1,867	$797,829
2016	258	2,091	$1,465,946
2017	281	2,128	$1,451,843
2018	309	1,886	$2,004,596
2019	321	2,041	$2,899,420
2020	356	2,277	$4,298,195
2021	380	2,450	$4,552,751
2022	407	2,504	$5,285,864
2023	406	2,319	$5,146,658
2024	431	2,375	$6,249,287

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	121	$45,053
2016	N/R	193	$36,730
2017	31	132	$38,788
2018	N/R	74	$9,645
2019	N/R	53	$5,257
2020	N/R	90	$31,204
2021	11	93	$6,149
2022	N/R	85	$3,280
2023	N/R	84	$17,998
2024	N/R	28	$825

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	538	1,826	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	261	1,273	$69
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	306	683	$63
36415	Insertion of needle into vein for collection of blood sample	583	2,337	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	585	2,655	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	73	2,044	$1,207,700
Brukinsa	Zanubrutinib	72	2,160	$1,070,427
Lenalidomide	Lenalidomide	38	1,064	$567,937
Calquence	Acalabrutinib Maleate	24	720	$354,949
Jakafi	Ruxolitinib Phosphate	20	600	$340,373

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$600
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	137	$3,788	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Veerpal Singh, MBBS, M.D.?

Tedicare shows public-source Medicare data for Veerpal Singh, MBBS, M.D. (NPI 1295952596), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Veerpal Singh, MBBS, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Veerpal Singh, MBBS, M.D.?

Veerpal Singh, MBBS, M.D. is linked to ILLINOIS CANCER SPECIALISTS (billing NPI 1164483913) in the available physician profile data.

Does Veerpal Singh, MBBS, M.D. have Open Payments data?

Veerpal Singh, MBBS, M.D. has 137 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.